When was Apexigen founded?

Apexigen was founded in 2010 and raised its 1st funding round 3 years after it was founded.

Where is Apexigen located?

Apexigen is headquartered in San Carlos, United States.

How many employees does Apexigen have?

As of Sep 30, 2026, the latest employee count at Apexigen is 8.

Is Apexigen a funded company?

Apexigen is a funded company, having raised a total of $158M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 06, 2013.

When was the latest funding round of Apexigen?

Apexigen's latest funding was a $***** Post IPO round on Feb 10, 2023, with participation from 0 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $4.78B in funding in 2026 to date.

Where does Apexigen rank among its competitors?

Apexigen ranks 969th amongst 3477 active competitors, of which 1140 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Apexigen?

Apexigen's top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Apexigen - 2026 Company Profile, Team, Funding, Competitors & Financials

Apexigen is an acqui-hired company based in San Carlos (United States), founded in 2010. It operates as a Specialty company that develops anti-body therapeutics for the treatment of cancer. Apexigen has raised $158M in funding from investors like Decheng Capital, Amkey Ventures and VI Ventures. The company has 3477 active competitors, including 1140 funded and 795 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Apexigen is a clinical stage biopharmaceutical company that develops anti-body therapeutics for the treatment of cancer using its proprietary antibody drug discovery platform, APXiMAB. The company's immuno-oncology drug candidate, APX005M, is a potent immune-activating antibody against CD40 currently in Phase 1 clinical development

Website: apexigen.com
Email ID: *****@apexigen.com

Key Metrics

Founded Year

2010

Location

San Carlos, United States

Stage

Acqui-Hired

Total Funding

$158M in 5 rounds

Latest Funding Round

Post IPO, Feb 10, 2023, $*****

Investors

Decheng Capital & 19 more

Ranked

969^th among 3477 active competitors

Employee Count

8 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3102 more

View Apexigen's full profile

Apexigen is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Apexigen, Inc. CIN: 1814140 , United States, Active		-	28 (As on Dec 31, 2022)	-

Apexigen has raised a total funding of $158M over 5 rounds. Its first funding round was on Aug 06, 2013. Apexigen has 20 institutional investors.

Here is the list of recent funding rounds of Apexigen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 10, 2023	5720816	Post IPO	1861855	5478099	5143186	4098435
Dec 11, 2019	4511355	Series C	1892292	4075802	3429046	Oceanpine Capital
Aug 08, 2018	4942964	Series C	3114581	4479492	3E Bioventures Capital & 2 more	Delian Capital

Access funding benchmarks and valuations. Sign up today!

View details of Apexigen's funding rounds and investors

Apexigen's employee count trend

Apexigen has 8 employees as of Sep 26. Here is Apexigen's employee count trend over the years:

Uncover Apexigen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Apexigen include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Apexigen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
969th	Apexigen 2010, San Carlos (United States), Acqui-Hired	Specialty company that develops anti-body therapeutics for the treatment of cancer	$158M	Decheng Capital, LDV Partners & 18 others	41/100